The news agency added it was unclear how much Eli Lilly (NYSE:LLY) may have paid physicians to promote its drug Zepound as it was only recently approved for weight loss. Zepound has the same ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback